Simplex Trading, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Simplex Trading, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	BUY	$0.21 - $0.43 $191 - $392	913 Added 7.49%	13,095 $2,000
Q3 2023 Nov 01, 2023	BUY	$0.28 - $0.93 $2,938 - $9,760	10,495 Added 622.11%	12,182 $3,000
Q2 2023 Aug 04, 2023	BUY	$0.55 - $1.26 $927 - $2,125	1,687 New	1,687 $1,000
Q4 2022 Feb 02, 2023	SELL	$1.02 - $7.48 $5,844 - $42,860	-5,730 Reduced 45.99%	6,728 $7,000
Q3 2022 Nov 04, 2022	BUY	$6.04 - $9.66 $53,792 - $86,031	8,906 Added 250.73%	12,458 $93,000
Q2 2022 Aug 03, 2022	SELL	$4.99 - $8.96 $302,364 - $542,922	-60,594 Reduced 94.46%	3,552 $22,000
Q1 2022 May 02, 2022	BUY	$3.84 - $9.74 $208,250 - $528,219	54,232 Added 547.02%	64,146 $532,000
Q4 2021 Feb 23, 2022	BUY	$5.12 - $8.19 $50,759 - $81,195	9,914 New	9,914 $51,000
Q4 2020 Feb 02, 2021	SELL	$7.98 - $12.29 $42,373 - $65,259	-5,310 Closed	0 $0
Q3 2020 Oct 14, 2020	BUY	$7.96 - $12.42 $42,267 - $65,950	5,310 New	5,310 $43,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.